PF-03526299

PF-03526299 is a small molecule investigational drug developed by Pfizer for the treatment of allergic asthma. It was designed as a novel anti-inflammatory agent intended to attenuate allergen-induced airway responses in patients with mild asthma. The drug was administered via inhalation and evaluated in several early-phase clinical trials to assess its effects on lung function, safety, tolerability, and pharmacokinetics compared to placebo and fluticasone (a standard steroid inhaler). Despite initial studies suggesting potential benefit in reducing bronchial inflammation following allergen challenge, development of PF-03526299 has been discontinued[2][3][4][5].